In 2009, Bendalis GmbH entered into partnership with EUSA Pharma, which has operations in the USA and Europe, for distribution of Caphosol®. Since the beginning of 2011, Bendalis GmbH has had a copromotion agreement with Riemser Arzneimittel AG for ALOXI® (palonosetron), an innovative 5-HT3 receptor antagonist for prophylaxis of chemotherapy-induced nausea and vomiting (CINV).
